The present invention relates to industrially feasible and safe process for preparing 2",4"-di-O-benzoyl-1 l-N-(4-Azidobutyl)-6-0-methy(erythromycin and its impurity.
The present invention relates to advantageous process for the~~pTeparauon of 10,1 l-Dihydro-10-oxo5H-dibenz[b,f]azepine-5-carboxamide and its intermediate.
The present invention relates to an improved, robust and industrially feasible process for preparing 5-Aminolevulinic acid hydrochloride and its novel intermediates.
The present invention relates to an improved process for preparing ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzainido)propanoate of Formula
3. It is a key intermediate to prepare Dabigatran of Formula-1 and Dabigatran etexilate of Formula-2. The present invention relates to safe, economical, robust and ind...
The present invention relates to improved, safe and industrially applicable enantioseleclive enzymatic process for preparing (S)-Ethyl-3-cyano-5-methylhexanoate
The present invention relates to an improved purification process for l-(3-(trif!uoromethyI)-5>6-dihydro-[l)254]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyI)butane-l,3-dione of formula-2. Moreover, the present invention provides robust, industrially applicable process for preparing l-(3-(trifluoromethyl...
The present invention relates to an advantageous, commercially viable, industrially feasible process for preparing 7-[(3R)-3-amino-l-oxo-4-(2)4)5-trifluorophenyl) butyl]-5,6,758-tetrahydro-3- (trifluoromethy^-l^^-triazolo^S-a] pyrazine phosphate monohydrate of formula-2 and its purification.
The present invention relates to an advantageous, industrially feasible process for preparing (S)-3-(4-(2-chloro-5-iodobenzyl)phenoxy) tetrahydrofuran.
The present invention relates to improved, advantageous, safe, robust process for preparing 1-[[2'-(2,5-dihydro-5-oxo-l,2,4-oxadiazol-3-yl)[l,r-biphenyl]-4-yl]methyl]-2-ethoxy-lH-benzimidazole-7-carboxylic acid of formula-1 comprises;
The present invention relates to process for the preparation of sodium [(2S,5R)-2-carbamoyl-7-oxo-l,6-diazabicyclo[3.2.1]octan-6-yl] sulfate of formula-1
The present invention relates to process for preparing non-pharmacopoeial impurities 3-carbamoyl-5-methylhexanoic acid of formula-2 and 2-(2-amino-2-oxoethyl)-4-methylpentanoic acid of formula-3
Charges
13 Crore
12 June 2002
State Bank Of India
12 Crore
25 July 1996
State Bank Of Hyderabad
50 Lak
28 September 1992
State Bank Of Hyderabad
45 Lak
07 August 1990
A.p. State Financial Corporation
1 Lak
22 July 1987
State Bank Of Hyderabad
21 Lak
25 June 1985
State Bank Of Hyderabad
19 Lak
07 September 1981
State Bank Of Hyderabad
2 Lak
13 June 1980
State Bank Of Hyderabad
2 Lak
27 March 1980
Andhra Pradesh State Financial Corporation
7 Lak
12 June 2002
State Bank Of India
0
25 July 1996
State Bank Of Hyderabad
0
25 June 1985
State Bank Of Hyderabad
0
07 August 1990
A.p. State Financial Corporation
0
07 September 1981
State Bank Of Hyderabad
0
27 March 1980
Andhra Pradesh State Financial Corporation
0
28 September 1992
State Bank Of Hyderabad
0
22 July 1987
State Bank Of Hyderabad
0
13 June 1980
State Bank Of Hyderabad
0
12 June 2002
State Bank Of India
0
25 July 1996
State Bank Of Hyderabad
0
25 June 1985
State Bank Of Hyderabad
0
07 August 1990
A.p. State Financial Corporation
0
07 September 1981
State Bank Of Hyderabad
0
27 March 1980
Andhra Pradesh State Financial Corporation
0
28 September 1992
State Bank Of Hyderabad
0
22 July 1987
State Bank Of Hyderabad
0
13 June 1980
State Bank Of Hyderabad
0
Documents
Form ADT-1-17122020_signed
Copy of written consent given by auditor-15122020
Copy of the intimation sent by company-15122020
Copy of resolution passed by the company-15122020
Form CHG-1-01102020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20200930
Optional Attachment-(1)-29092020
Instrument(s) of creation or modification of charge;-29092020
Form AOC-4(XBRL)-22012020_signed
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-17012020
Optional Attachment-(1)-17012020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-17012020
XBRL document in respect Consolidated financial statement-17012020
Form MGT-7-06012020_signed
List of share holders, debenture holders;-31122019
Form ADT-1-23112019_signed
Copy of resolution passed by the company-23112019
Copy of the intimation sent by company-23112019
Copy of written consent given by auditor-23112019
Form MGT-7-10042019_signed
XBRL document in respect Consolidated financial statement-04042019
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-04042019
Copy of MGT-8-04042019
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-04042019
Optional Attachment-(1)-04042019
List of share holders, debenture holders;-04042019